Cargando…
Osteopontin as a Biomarker in Chronic Kidney Disease
Osteopontin (OPN) is a ubiquitously expressed protein with a wide range of physiological functions, including roles in bone mineralization, immune regulation, and wound healing. OPN has been implicated in the pathogenesis of several forms of chronic kidney disease (CKD) where it promotes inflammatio...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216241/ https://www.ncbi.nlm.nih.gov/pubmed/37239027 http://dx.doi.org/10.3390/biomedicines11051356 |
_version_ | 1785048250882981888 |
---|---|
author | Sinha, Satyesh K. Mellody, Michael Carpio, Maria Beatriz Damoiseaux, Robert Nicholas, Susanne B. |
author_facet | Sinha, Satyesh K. Mellody, Michael Carpio, Maria Beatriz Damoiseaux, Robert Nicholas, Susanne B. |
author_sort | Sinha, Satyesh K. |
collection | PubMed |
description | Osteopontin (OPN) is a ubiquitously expressed protein with a wide range of physiological functions, including roles in bone mineralization, immune regulation, and wound healing. OPN has been implicated in the pathogenesis of several forms of chronic kidney disease (CKD) where it promotes inflammation and fibrosis and regulates calcium and phosphate metabolism. OPN expression is increased in the kidneys, blood, and urine of patients with CKD, particularly in those with diabetic kidney disease and glomerulonephritis. The full-length OPN protein is cleaved by various proteases, including thrombin, matrix metalloproteinase (MMP)-3, MMP-7, cathepsin-D, and plasmin, producing N-terminal OPN (ntOPN), which may have more detrimental effects in CKD. Studies suggest that OPN may serve as a biomarker in CKD, and while more research is needed to fully evaluate and validate OPN and ntOPN as CKD biomarkers, the available evidence suggests that they are promising candidates for further investigation. Targeting OPN may be a potential treatment strategy. Several studies show that inhibition of OPN expression or activity can attenuate kidney injury and improve kidney function. In addition to its effects on kidney function, OPN has been linked to cardiovascular disease, which is a major cause of morbidity and mortality in patients with CKD. |
format | Online Article Text |
id | pubmed-10216241 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102162412023-05-27 Osteopontin as a Biomarker in Chronic Kidney Disease Sinha, Satyesh K. Mellody, Michael Carpio, Maria Beatriz Damoiseaux, Robert Nicholas, Susanne B. Biomedicines Review Osteopontin (OPN) is a ubiquitously expressed protein with a wide range of physiological functions, including roles in bone mineralization, immune regulation, and wound healing. OPN has been implicated in the pathogenesis of several forms of chronic kidney disease (CKD) where it promotes inflammation and fibrosis and regulates calcium and phosphate metabolism. OPN expression is increased in the kidneys, blood, and urine of patients with CKD, particularly in those with diabetic kidney disease and glomerulonephritis. The full-length OPN protein is cleaved by various proteases, including thrombin, matrix metalloproteinase (MMP)-3, MMP-7, cathepsin-D, and plasmin, producing N-terminal OPN (ntOPN), which may have more detrimental effects in CKD. Studies suggest that OPN may serve as a biomarker in CKD, and while more research is needed to fully evaluate and validate OPN and ntOPN as CKD biomarkers, the available evidence suggests that they are promising candidates for further investigation. Targeting OPN may be a potential treatment strategy. Several studies show that inhibition of OPN expression or activity can attenuate kidney injury and improve kidney function. In addition to its effects on kidney function, OPN has been linked to cardiovascular disease, which is a major cause of morbidity and mortality in patients with CKD. MDPI 2023-05-04 /pmc/articles/PMC10216241/ /pubmed/37239027 http://dx.doi.org/10.3390/biomedicines11051356 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sinha, Satyesh K. Mellody, Michael Carpio, Maria Beatriz Damoiseaux, Robert Nicholas, Susanne B. Osteopontin as a Biomarker in Chronic Kidney Disease |
title | Osteopontin as a Biomarker in Chronic Kidney Disease |
title_full | Osteopontin as a Biomarker in Chronic Kidney Disease |
title_fullStr | Osteopontin as a Biomarker in Chronic Kidney Disease |
title_full_unstemmed | Osteopontin as a Biomarker in Chronic Kidney Disease |
title_short | Osteopontin as a Biomarker in Chronic Kidney Disease |
title_sort | osteopontin as a biomarker in chronic kidney disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216241/ https://www.ncbi.nlm.nih.gov/pubmed/37239027 http://dx.doi.org/10.3390/biomedicines11051356 |
work_keys_str_mv | AT sinhasatyeshk osteopontinasabiomarkerinchronickidneydisease AT mellodymichael osteopontinasabiomarkerinchronickidneydisease AT carpiomariabeatriz osteopontinasabiomarkerinchronickidneydisease AT damoiseauxrobert osteopontinasabiomarkerinchronickidneydisease AT nicholassusanneb osteopontinasabiomarkerinchronickidneydisease |